MARION, AL — August 4, 2026 — Leads & Copy — Callan JMB Inc. (NASDAQ: CJMB), an integrative logistics company serving the healthcare industry and emergency management agencies, has entered into a strategic support services agreement with Cavalry 1838 Equine Biosciences. This agreement expands Callan JMB’s recurring infrastructure services business by securing a 60% participation in the enterprise’s revenue.
The partnership is a key component of Callan JMB’s Atlas Complex strategy, which aims to develop an integrated healthcare and life sciences campus. Organizations operating within the Atlas Complex can leverage shared operational infrastructure and specialized support services, reducing their capital requirements while focusing on research, product development, and commercialization.
Cavalry 1838 is developing an equine-derived biologics enterprise focused on producing pharmaceutical-grade serum, plasma, and specialty biologic products for pharmaceutical manufacturers, biotechnology companies, veterinary biologics developers, and research organizations. The enterprise plans a phased commercialization, starting with serum and plasma production before moving into higher-value biologic products and specialty therapeutic applications.
Under the long-term operational support agreement, Callan JMB will provide the necessary infrastructure and operational services for Cavalry 1838’s commercialization activities. The company anticipates the enterprise’s underlying business plan to generate annual revenues between $12 million and $25 million within seven years, based on its base-case scenario.
Callan JMB’s role will encompass providing a range of operational support functions, including regulatory compliance and quality management systems, logistics and supply chain management, warehousing and distribution, administrative and shared business services, scientific and operational support, commercialization support, and operational infrastructure management.
Cavalry 1838’s operations in Alabama will be situated at the Atlas Complex, utilizing its Equine Center, which is designed to support specialized life sciences, veterinary, biologics, and research initiatives requiring professionally managed equine facilities integrated with pharmaceutical-grade operational infrastructure.
The proposed enterprise is expected to operate with Alabama as its corporate headquarters and operational support center, and Kansas serving as the primary serum collection and production facility. Alabama operations at the Atlas Complex will include research and development, quality control, regulatory management, distribution activities, and the Equine Center.
Wayne Williams, President and CEO of Callan JMB, stated, “Every organization that establishes operations at the Atlas Complex has the potential to expand Callan JMB’s portfolio of recurring infrastructure and operational services. Our strategy is to provide the regulatory, logistics, quality and operational expertise organizations need to commercialize innovative products while allowing them to remain focused on science, manufacturing and product development.”
Callan JMB continues to evaluate opportunities to expand the Atlas Complex through strategic relationships with organizations in pharmaceutical manufacturing, biologics, healthcare logistics, medical research, and related life sciences sectors. The Atlas Complex is a purpose-built healthcare and life sciences campus in Marion, Alabama, designed to offer integrated operational infrastructure.
Source: Callan JMB Inc.
